Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History OTLK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics OTLK

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

OUTLOOK THERAPEUTICS INC

OTLK
Current price
2.18 USD -0.13 USD (-5.63%)
Last closed 2.31 USD
ISIN US69012T3059
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 93 421 072 USD
Yield for 12 month -73.19 %
1Y
3Y
5Y
10Y
15Y
OTLK
21.11.2021 - 28.11.2021

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey. Address: 111 S. Wood Avenue, Iselin, NJ, United States, 08830

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

8.60 USD

P/E Ratio

0.53

Dividend Yield

Financials OTLK

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures OTLK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+170 124 USD

Last Year

Current Quarter

Last Quarter

+170 124 USD

Current Year

+85 062 USD

Last Year

-26 453 000 USD

Current Quarter

Last Quarter

+170 124 USD
EBITDA -76 323 144 USD
Operating Margin TTM
Price to Earnings 0.53
Return On Assets TTM -122.34 %
PEG Ratio
Return On Equity TTM -3.65 %
Wall Street Target Price 8.60 USD
Revenue TTM 5 853 537 USD
Book Value -0.99 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 658.30 %
Dividend Yield
Gross Profit TTM -41 763 048 USD
Earnings per share 4.09 USD
Diluted Eps TTM 4.09 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation OTLK

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 0.53
Forward PE 2.85
Enterprise Value Revenue 26.10
Price Sales TTM 13.27
Enterprise Value EBITDA -4.13
Price Book MRQ 10.19

Technical Indicators OTLK

For 52 Weeks

0.87 USD 8.70 USD
50 Day MA 1.74 USD
Shares Short Prior Month 2 739 054
200 Day MA 2.56 USD
Short Ratio 3.12
Shares Short 2 190 871
Short Percent 7.83 %